1. Home
  2. LH vs VTRS Comparison

LH vs VTRS Comparison

Compare LH & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laboratory Corporation of America Holdings

LH

Laboratory Corporation of America Holdings

HOLD

Current Price

$255.36

Market Cap

21.7B

Sector

Health Care

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$15.32

Market Cap

18.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LH
VTRS
Founded
1971
1961
Country
United States
United States
Employees
70000
30000
Industry
Medical Specialities
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7B
18.3B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
LH
VTRS
Price
$255.36
$15.32
Analyst Decision
Buy
Buy
Analyst Count
9
4
Target Price
$311.33
$13.50
AVG Volume (30 Days)
512.3K
8.1M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.12%
3.21%
EPS Growth
18.33
N/A
EPS
3.35
0.15
Revenue
$13,951,700,000.00
$14,299,900,000.00
Revenue This Year
$8.26
$4.41
Revenue Next Year
$4.81
$1.96
P/E Ratio
$76.33
$101.83
Revenue Growth
7.25
N/A
52 Week Low
$241.81
$8.63
52 Week High
$293.72
$17.53

Technical Indicators

Market Signals
Indicator
LH
VTRS
Relative Strength Index (RSI) 42.18 41.18
Support Level $248.61 $12.90
Resistance Level $274.48 $16.51
Average True Range (ATR) 5.90 0.45
MACD -0.43 -0.09
Stochastic Oscillator 12.60 25.45

Price Performance

Historical Comparison
LH
VTRS

About LH Laboratory Corporation of America Holdings

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: